Related references
Note: Only part of the references are listed.Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma
Cristina Zahonero et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas
Martin J. van den Bent et al.
NEURO-ONCOLOGY (2015)
Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384
Yanni Zhu et al.
CANCER BIOLOGY & THERAPY (2014)
Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
Oscar Gallego et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
Peter M. Ellis et al.
LANCET ONCOLOGY (2014)
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2014)
EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis
Krishna M. Talasila et al.
ACTA NEUROPATHOLOGICA (2013)
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
Nicholas J. Szerlip et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib-A Phase II Trial
Monika E. Hegi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Oncogenic EGFR Signaling Activates an mTORC2-NF-κB Pathway That Promotes Chemotherapy Resistance
Kazuhiro Tanaka et al.
CANCER DISCOVERY (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
W. K. Alfred Yung et al.
NEURO-ONCOLOGY (2010)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
Teri N. Kreisl et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues
Craig Horbinski et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples
Koji Yoshimoto et al.
CLINICAL CANCER RESEARCH (2008)
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy
Fred R. Hirsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
Paul D. Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J. F. de Groot et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
Jeffrey A. Engelman et al.
CANCER RESEARCH (2007)
Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma
Jean-Francois Mineo et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Gefitinib in patients with progressive high-grade gliomas:: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
E. Franceschi et al.
BRITISH JOURNAL OF CANCER (2007)
Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells
DB Ramnarain et al.
CANCER RESEARCH (2006)
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
Marileila Varella-Garcia
DIAGNOSTIC PATHOLOGY (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Share Paper
